Entrada Therapeutics, Inc. financial data

Symbol
TRDA on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1634% % 234%
Debt-to-equity 20% % -51%
Return On Equity -40% % -335%
Return On Assets -33% % -376%
Operating Margin -621% % -2885%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38,284,313 shares 0.87%
Common Stock, Shares, Outstanding 38,284,221 shares 1.9%
Entity Public Float $191,200,000 USD -51%
Common Stock, Value, Issued $4,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 41,371,486 shares 11%
Weighted Average Number of Shares Outstanding, Diluted 41,371,486 shares 6.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $25,421,000 USD -88%
Research and Development Expense $142,269,000 USD 14%
General and Administrative Expense $41,050,000 USD 6.7%
Operating Income (Loss) $157,898,000 USD -436%
Income Tax Expense (Benefit) $924,000 USD 7.6%
Net Income (Loss) Attributable to Parent $143,750,000 USD -319%
Earnings Per Share, Basic -3.47 USD/shares -297%
Earnings Per Share, Diluted -3.47 USD/shares -307%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $90,394,000 USD -11%
Cash, Cash Equivalents, and Short-term Investments $295,700,000 USD -30%
Assets, Current $306,252,000 USD -30%
Property, Plant and Equipment, Net $7,313,000 USD -33%
Operating Lease, Right-of-Use Asset $60,451,000 USD -15%
Other Assets, Noncurrent $70,000 USD -75%
Assets $377,378,000 USD -28%
Accounts Payable, Current $2,289,000 USD -46%
Employee-related Liabilities, Current $8,045,000 USD 8.8%
Accrued Liabilities, Current $17,682,000 USD 33%
Liabilities, Current $24,451,000 USD -38%
Operating Lease, Liability, Noncurrent $46,794,000 USD -9.4%
Liabilities $71,245,000 USD -27%
Accumulated Other Comprehensive Income (Loss), Net of Tax $652,000 USD
Retained Earnings (Accumulated Deficit) $273,094,000 USD -111%
Stockholders' Equity Attributable to Parent $306,133,000 USD -29%
Liabilities and Equity $377,378,000 USD -28%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $38,507,000 USD -51%
Net Cash Provided by (Used in) Financing Activities $350,000 USD 70%
Net Cash Provided by (Used in) Investing Activities $4,783,000 USD -82%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 38,284,221 shares 1.9%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $33,374,000 USD -4102%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $94,344,000 USD -10%
Deferred Tax Assets, Valuation Allowance $108,053,000 USD 72%
Deferred Tax Assets, Gross $125,985,000 USD 49%
Operating Lease, Liability $50,932,000 USD -14%
Depreciation $4,096,000 USD 8.6%
Payments to Acquire Property, Plant, and Equipment $1,144,000 USD 37%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $143,055,000 USD -319%
Lessee, Operating Lease, Liability, to be Paid $67,631,000 USD -16%
Property, Plant and Equipment, Gross $17,247,000 USD -15%
Operating Lease, Liability, Current $4,138,000 USD -45%
Lessee, Operating Lease, Liability, to be Paid, Year Two $9,083,000 USD 2.9%
Lessee, Operating Lease, Liability, to be Paid, Year One $8,109,000 USD -33%
Operating Lease, Weighted Average Discount Rate, Percent 0.0815 pure 0.12%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $16,699,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three $9,349,000 USD 2.9%
Deferred Tax Assets, Operating Loss Carryforwards $49,578,000 USD 3822%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $9,622,000 USD 2.9%
Additional Paid in Capital $578,571,000 USD 3.7%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $19,609,000 USD 9.5%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%